SLC5A2 and cardiovascular disorder: However, a clinical trial showed that treatment with the SGLT2 inhibitor dapagliflozin reduced the risk of cardiovascular disease-related death in patients with or without type 2 diabetes [7], suggesting that the drug reduces the risk of cardiac complications independently of its blood glucose-lowering properties.